Acasti Pharma Q3 net loss $3.9M; cash $31.3M; pipeline advances to Phase 3

Grace Therapeutics, Inc.

2022-Q3 EPS reported -$0.30

Net loss $3.9M ($0.09 loss per share) vs $3.8M loss a year ago.
Cash, equivalents and ST investments $31.3M as of Dec 31, 2022; funds operations into Q2 2024.
GTX-104: Expects FDA Type C meeting in Q1 2023; may initiate Phase 3 safety study.
GTX-102 PK bridging study met all primary endpoints; Phase 3 planning underway.
GTX-101 PK study met all primary endpoints; multiple ascending dose study planned in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Grace Therapeutics, Inc. reported financial results for the third quarter ended December 31, 2022.

Period: the third quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 14, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-002698

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.